Side-by-side · Research reference

GHK-CuvsTB-500

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticReviewed8/47 cited

BPhase 2Reviewed8/46 cited

GHK-Cu

Tripeptide · Skin / Hair / Wound Healing

1–2 mgSQ dosePickart 2018

HumanMechanisticPickart 2018 Zink 2003

HoursHalf-life

SQ or topical · Local · Daily or 2-3×/week

TB-500

Thymosin β4 fragment · Healing

2 mgPer doseGoldstein 2012

Phase 2Evidence levelGoldstein 2012

~2 hrHalf-life

SQ or IM · Multiple sites · 2–3×/week

01Mechanism of Action

Parameter

GHK-Cu

TB-500

Primary target

Copper-dependent enzymes (lysyl oxidase, SOD); regulator of >4000 human genesPickart 2018

G-actin (sequestering) + cell-surface integrinsGoldstein 2012

Pathway

Cu(II) delivery via GHK chelation → ↑collagen / elastin / GAG synthesis; ↓inflammatory cytokines; ↑hair follicle growth-factor signalingPickart 2018

Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012 Malinda 1999

Downstream effect

Skin firmness + texture improvement, accelerated wound healing, hair regrowth, anti-inflammatory actionPickart 2018 Zink 2003

Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012

Feedback intact?

Replaces declining endogenous levels

Endogenous protein at baseline; supplementation amplifies

Origin

Endogenous tripeptide first isolated from human plasma; declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60Pickart 2018

17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012

Antibody development

—

02Dosage Protocols

Parameter

GHK-Cu

TB-500

Standard SQ dose

1–2 mg / dayPickart 2018

Anecdotal injectable range; topical creams use 0.1–2% solutions.

—

Topical concentration

0.1–2.0% in serum / cream

—

Frequency

Daily or 2–3× per week (SQ)

2× per week (loading); then 1× per week (maintenance)

Lower / starter dose

0.5 mg / day SQ

1 mg per injection

Evidence basis

Human-mechanistic + topical clinical studiesPickart 2018

Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012

Duration

8–12 weeks for visible skin / hair effect

4–8 weeks loading; longer maintenance for chronic injury

Reconstitution

Bacteriostatic water; light-protected

Bacteriostatic water, 1–2 mL per 5 mg vial

Timing

No specific time; evening preferred for topicals

Evening or pre-rest preferred (anecdotal)

Half-life

Hours (estimated; rapid tissue uptake)

~2 hours (estimated; tissue uptake longer)

Standard dose

—

2 mg per injectionGoldstein 2012

Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.

04Side Effects & Safety

Parameter

GHK-Cu

TB-500

Injection site reaction

Erythema, mild pruritus (common)

Mild erythema, transient pain

Topical irritation

Mild redness, transient stinging

—

Copper accumulation

Theoretical with very high chronic doses

—

Allergic reaction

Rare hypersensitivity to copper

—

Pregnancy / OB

Avoid topical and SQ — insufficient data

Avoid

Wilson disease

Contraindicated

—

GI symptoms

—

Rare nausea (anecdotal)

Cancer risk

—

Theoretical via angiogenesis pathway

Lethargy / fatigue

—

Reported anecdotally during loading phase

Antibody formation

—

No data (no long-term human trials)

Long-term safety

—

Unknown beyond Phase 2

Absolute Contraindications

GHK-Cu

·Wilson disease (copper-overload disorder)
·Pregnancy / breastfeeding
·Known copper hypersensitivity

TB-500

·Active malignancy (theoretical angiogenesis concern)
·Pregnancy / breastfeeding

Relative Contraindications

GHK-Cu

·Hemochromatosis (copper-iron crosstalk theoretical)
·Concurrent copper-chelator therapy

TB-500

·Cancer history
·Concurrent VEGF inhibitor therapy

05Administration Protocol

Parameter

GHK-Cu

TB-500

1. Reconstitution

Add 1–2 mL bacteriostatic water to a 50 mg vial → 25–50 mg/mL. Use within 30 days, refrigerated.

Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.

2. Injection site

SQ — local to the area of interest (face, scalp) for skin / hair indications. Rotate sites.

SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.

3. Timing

Anytime; evening preferred. Topical: apply to clean dry skin.

Evening or pre-sleep is most common anecdotal timing.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, light-protected, ≤30 days.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

5. Needle

30–31G, short (4–6 mm) for shallow SQ. Topical: clean fingertips, no needle.

27–31G, 4–8 mm insulin syringe.

06Stack Synergy

GHK-Cu

+ BPC-157

Moderate

View BPC-157 →

GHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.

GHK-Cu: 1–2 mg SQ · daily near wound
BPC-157: 250–500 mcg SQ · daily near wound
Primary benefit: Combined ECM rebuilding + angiogenesis for tissue repair

TB-500

+ BPC-157

Strong

View BPC-157 →

TB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.

TB-500: 2 mg SQ · 2× per week
BPC-157: 250–500 mcg SQ · daily
Primary benefit: Combined angiogenesis + cell migration for tendon/ligament/muscle repair